<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>Iran Medical Council</PublisherName>
				<JournalTitle>Journal of Iranian Medical Council</JournalTitle>
				<Issn>2645-338X</Issn>
				<Volume>1</Volume>
				<Issue>1</Issue>
				<PubDate PubStatus="epublish">
					<Year>2018</Year>
					<Month>07</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>The Protective Effect of the Gallic Acid Against TNBS-induced Ulcerative Colitis in Rats: Role of Inflammatory Parameters</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>34</FirstPage>
			<LastPage>42</LastPage>
			<ELocationID EIdType="pii">66219</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Bita</FirstName>
					<LastName>Khodayar</LastName>
<Affiliation>Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Mohammad Hossein</FirstName>
					<LastName>Farzaei</LastName>

						<AffiliationInfo>
						<Affiliation>Pharmaceutical Sciences Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran</Affiliation>
						</AffiliationInfo>

						<AffiliationInfo>
						<Affiliation>Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran</Affiliation>
						</AffiliationInfo>

</Author>
<Author>
					<FirstName>Amir Hossein</FirstName>
					<LastName>Abdolghaffari</LastName>

						<AffiliationInfo>
						<Affiliation>Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran</Affiliation>
						</AffiliationInfo>

						<AffiliationInfo>
						<Affiliation>Gastrointestinal Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran</Affiliation>
						</AffiliationInfo>

						<AffiliationInfo>
						<Affiliation>Toxicology and Diseases Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical
Sciences, Tehran, Iran</Affiliation>
						</AffiliationInfo>

</Author>
<Author>
					<FirstName>Roodabeh</FirstName>
					<LastName>Bahramsoltani</LastName>
<Affiliation>Department of Pharmacy in Persian Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Maryam</FirstName>
					<LastName>Baeeri</LastName>
<Affiliation>Toxicology and Diseases Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Fatemeh</FirstName>
					<LastName>Sabbagh Ziarani</LastName>
<Affiliation>Department of Anatomy, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Mojdeh</FirstName>
					<LastName>Mohammadi</LastName>
<Affiliation>Department of Toxicology and Pharmacology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Roja</FirstName>
					<LastName>Rahimi</LastName>
<Affiliation>Department of Pharmacy in Persian Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Mohammad</FirstName>
					<LastName>Abdollahi</LastName>

						<AffiliationInfo>
						<Affiliation>Toxicology and Diseases Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical
Sciences, Tehran, Iran</Affiliation>
						</AffiliationInfo>

						<AffiliationInfo>
						<Affiliation>Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran,
Iran</Affiliation>
						</AffiliationInfo>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2018</Year>
					<Month>07</Month>
					<Day>21</Day>
				</PubDate>
			</History>
		<Abstract>Background: Ulcerative Colitis (UC) is an Inflammatory Bowel Disease (IBD) that causes long-lasting inflammation and ulcers in digestive tract. The current study aimed to evaluate the protective effects of gallic acid on the 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced UC in rats. &lt;br&gt;Methods: Forty-two adult Wistar rats were divided into seven groups (n=7) and UC was induced in six groups using TNBS solution. They received different daily doses of gallic acid (25, 50, 75 and 100 &lt;em&gt;mg/kg/day&lt;/em&gt;, p.o). On the 11th day, the colon tissues were removed and examined regarding the macroscopic and histopathology lesions. Also, Disease Activity Index (DAI) and Myeloperoxidase (MPO) activity were measured in the colon homogenate.&lt;br&gt;Results: Pretreatment with this natural agent remarkably reduced the macroscopic scores of colon in rats with UC in comparison with the control group. DAI was also reduced by gallic acid significantly. Histopathological findings confirmed the beneficial effects of gallic acidonthe animal model of UC. Gallic acid induced a significant decrease in the levels of inflammatory mediators like MPO.&lt;br&gt;Conclusion: We may conclude that gallic acid can be used as an effective medicine for treatment of UC in animal model, however it needs to be confirmed by human models.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Gallic acid</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Inflammatory bowel disease</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Ulcerative colitis</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Natural product</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">oxidative stress</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.jimc.ir/article_66219_f16ab670b34d848cb1cae71fff32a682.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
